top of page
The Professional Network for Healthcare Experts
Piramal Pharma completes acquisition of controlling stake in Yapan Bio to expand biologics CDMO capabilities
The acquisition makes Yapan Bio a Piramal Pharma subsidiary, strengthening the company's integrated biologics development and manufacturing offering for vaccines, biologics and antibody-drug conjugates.
nuaxia
2 days ago2 min read
Gland Pharma signs global sterile injectables CDMO deal with $90–100 million annual revenue potential
The long-term manufacturing agreement covers 55 oncology and non-oncology products across three Gland Pharma sites, with commercial revenue expected to begin in 2029.
nuaxia
Aug 102 min read
bottom of page